Shots:
- Nabla Bio has entered into a multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics, leveraging Nabla Bio’s Joint Atomic Model (JAM)
- Nabla Bio will deploy its proprietary JAM platform across Takeda’s early-stage programs to enable de novo antibody design for multiple targets, multi-specifics, challenging targets, & custom therapeutics
- As per the deal, Nabla Bio will receive double-digit million in upfront as well as research funding payments & is eligible for success-based milestones exceeding $1B in total
Ref: BusinessWire | Image: Nabla Bio & Takeda| Press Release
Related News:- Takeda’s Vonvendi Receives the US FDA’s Approval for Adults and Children with Von Willebrand Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
